前收市價 | 70.65 |
開市 | 70.65 |
買盤 | 72.00 |
賣出價 | 79.20 |
拍板 | 240.00 |
到期日 | 2024-10-18 |
今日波幅 | 70.65 - 70.65 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 10 |
(Bloomberg) -- The new class of weight-loss drugs being tested as cure-alls for everything from knee replacements to liver disease keeps throwing corners of the stock market into disarray.Most Read from BloombergBuzzFeed Struggles to Sell Owner of Hit YouTube Show ‘Hot Ones’Jain Global Raises $5.3 Billion, Secures Cash From Abu DhabiNvidia’s 13% Stock Rout Has Traders Scouring Charts for SupportHow Long Can High Rates Last? Bond Markets Say Maybe ForeverTech Hits Stocks as Nvidia Extends Selloff
Insulet (PODD) reports positive findings from the SECURE-T2D pivotal trial, the largest study of AID therapy in people with type 2 diabetes.
ClearBridge Investments, an investment management company, released its “ClearBridge Select Strategy” first quarter 2024 investor letter. A copy of the letter can be downloaded here. The positive momentum in 2023 continued in the first quarter of 2024, the stocks surged on the expectation of a soft landing of the economy and a slowdown in rate […]